Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison.
Prostate
; 77(6): 639-646, 2017 May.
Article
en En
| MEDLINE
| ID: mdl-28101887
ABSTRACT
BACKGROUND:
To perform a comparative effectiveness analyses between enzalutamide and abiraterone acetate in both the pre-docetaxel and post-docetaxel settings based on published phase III randomized trials.METHODS:
The primary measure of efficacy was the posterior probability that enzalutamide outperforms abiraterone acetate (AA) with prednisone in terms of overall survival (OS) on average. Indirect meta-estimates were generated from four randomized studies in the context of a Bayesian hierarchical model with study-specific efficacy estimates meta-analyzed on the log scale.RESULTS:
We found weak evidence that enzalutamide outperforms AA with prednisone in terms of OS in the pre-docetaxel and post-docetaxel settings. However, we found strong evidence that enzalutamide outperforms AA with prednisone in terms of radiographic PFS, time until PSA progression, and PSA response rate in both the pre- and post-docetaxel settings. Rates of grade 3 or worse adverse events were broadly similar between treatment (enzalutamide or AA) and control arms (placebo or placebo with prednisone) in all included randomized studies.CONCLUSIONS:
There is strong evidence that enzalutamide outperforms AA with prednisone in terms of radiographic PFS and PSA progression and PSA response rate but not OS in the pre and post-docetaxel settings. These results may further guide clinicians in making treatment recommendations for patients with advanced prostate cancer. Prostate 77 639-646, 2017. © 2017 Wiley Periodicals, Inc.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Feniltiohidantoína
/
Neoplasias de la Próstata Resistentes a la Castración
/
Androstenos
Tipo de estudio:
Clinical_trials
/
Guideline
/
Prognostic_studies
/
Systematic_reviews
Límite:
Humans
/
Male
Idioma:
En
Revista:
Prostate
Año:
2017
Tipo del documento:
Article
País de afiliación:
Singapur